Lifyorli (copackaged)

(Relacorilant)

Phase 3Small molecule

Lifyorli (copackaged) is a small molecule that works as a Glucocorticoid Receptor Antagonist.[2] It is being investigated across 7 indications, with its most advanced program in Phase 3.[1]

Lifyorli (copackaged) is one of 185 small molecule programs targeting Adrenal Gland Hyperfunction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

184

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Adrenal Gland HyperfunctionActive, not recruiting

AdenomaActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Cushing SyndromeActive, not recruiting

Alcohol DependenceActive, not recruiting

Liver DiseaseActive, not recruiting

Prostate CancerActive, not recruiting

Adrenal Gland HyperfunctionPhase 3

Active, not recruiting

AdenomaPhase 3

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Cushing SyndromePhase 3

Active, not recruiting

Alcohol DependencePreclinical

Active, not recruiting

Liver DiseasePhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lifyorli (copackaged)

CCorcept Therapeutics

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Ifex

BBaxter Healthcare Corporation

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Cushing Syndrome

NCT03604198

Phase 2Recruiting

Treatment

NCT06906341

Q1 2027

Phase 1Active, not recruiting

Prostate Cancer

NCT03674814

Q3 2027

Phase 2Recruiting

Pancreatic Adenocarcinoma

NCT07259317

Q2 2028

Phase 2Recruiting

Prostate Cancer

NCT05726292

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT05726292·90 enrolled

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Active, not recruiting·UUniversity of Chicago·Phase 1·NCT03674814·35 enrolled

Cushing syndrome2 trials

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Active, not recruiting·CCorcept Therapeutics·Phase 2·NCT03604198·125 enrolled

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Completed·CCorcept Therapeutics·Phase 3·NCT03697109·152 enrolled

Cardiac Repolarization1 trial

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Completed·CCorcept Therapeutics·Phase 1·NCT04795479·36 enrolled

Hepatic Impairment1 trial

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Completed·CCorcept Therapeutics·Phase 1·NCT06094725·30 enrolled

Nab-paclitaxel1 trial

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Completed·CCorcept Therapeutics·Phase 1/2·NCT02762981·85 enrolled

9 more indications

Oral1 trial

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Completed·CCorcept Therapeutics·Phase 1·NCT06094738·30 enrolled

Primary Peritoneal Cancer1 trial

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·CCorcept Therapeutics·Phase 2·NCT03776812·178 enrolled

Adenoma1 trial

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Completed·CCorcept Therapeutics·Phase 3·NCT04308590·137 enrolled

Tics1 trial

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Completed·CCorcept Therapeutics·Phase 1·NCT05347979·30 enrolled

Adrenocortical Carcinoma1 trial

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Completed·CCorcept Therapeutics·Phase 1·NCT04373265·15 enrolled

Primary Peritoneal1 trial

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active, not recruiting·CCorcept Therapeutics·Phase 3·NCT05257408·381 enrolled

Treatment1 trial

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Recruiting·CCorcept Therapeutics·Phase 2·NCT06906341·270 enrolled

Pancreatic Adenocarcinoma1 trial

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting·CCorcept Therapeutics·Phase 2·NCT07259317·60 enrolled

Unspecified4 trials

Relacorilant Food Effect Study in Healthy Subjects

Completed·CCorcept Therapeutics·Phase 1·NCT03442621·30 enrolled

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Completed·CCorcept Therapeutics·Phase 1·NCT03457597·27 enrolled

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Completed·CCorcept Therapeutics·Phase 1·NCT03512548·52 enrolled

Show 1 more trial

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Completed·CCorcept Therapeutics·Phase 1·NCT03540836·30 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 25, 2026

LIFYORLI (COPACKAGED)

NDA NDA220641

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Relacorilant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Relacorilant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Relacorilant. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220641). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Lifyorli (copackaged). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Corcept Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCorcept Therapeutics

Patent Landscape[5]

Patent Cliff

May 24, 2033

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11576907May 24, 2033

10456392May 24, 2033

9273047May 24, 2033

8859774May 24, 2033

12514849Dec 18, 2039

5 more patents

11925626Dec 18, 2039

11464764Apr 14, 2040

11285145May 26, 2041

12589094May 26, 2041

12152028Dec 22, 2041

Lifyorli (copackaged)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q2 2028

Trials by Indication[1]

Prostate Cancer2 trials

Cushing syndrome2 trials

Cardiac Repolarization1 trial

Hepatic Impairment1 trial

Nab-paclitaxel1 trial

Oral1 trial

Primary Peritoneal Cancer1 trial

Adenoma1 trial

Tics1 trial

Adrenocortical Carcinoma1 trial

Primary Peritoneal1 trial

Treatment1 trial

Pancreatic Adenocarcinoma1 trial

Unspecified4 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News